non-coding RNA
The company is assessing a variety of applications, including cancer early detection, using algorithms to analyze orphan noncoding RNA in blood.
With Low-Cost SARS-CoV-2 Assay, FYR Diagnostics Looks to Bypass Equipment Bottlenecks
The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
MiR Scientific Validates Urine-Based Cancer Tests, Awaits NY State Approval
The firm recently published a study describing three assays for prostate cancer and reporting their sensitivity and specificity in case-control cohort.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.